These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections. Morrill HJ; Pogue JM; Kaye KS; LaPlante KL Open Forum Infect Dis; 2015 Apr; 2(2):ofv050. PubMed ID: 26125030 [TBL] [Abstract][Full Text] [Related]
3. Continuous Evolution: Perspective on the Epidemiology of Carbapenemase Resistance Among Enterobacterales and Other Gram-Negative Bacteria. Hansen GT Infect Dis Ther; 2021 Mar; 10(1):75-92. PubMed ID: 33492641 [TBL] [Abstract][Full Text] [Related]
4. An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam. Wenzler E; Scoble PJ Infect Dis Ther; 2020 Dec; 9(4):769-784. PubMed ID: 33025557 [TBL] [Abstract][Full Text] [Related]
5. Carbapenem-resistant enterobacteriaceae: an emerging problem in children. Logan LK Clin Infect Dis; 2012 Sep; 55(6):852-9. PubMed ID: 22700827 [TBL] [Abstract][Full Text] [Related]
6. Risk Factors and Molecular Epidemiology of Complicated Intra-Abdominal Infections With Carbapenem-Resistant Enterobacteriaceae: A Multicenter Study in China. Liu J; Zhang L; Pan J; Huang M; Li Y; Zhang H; Wang R; Zhao M; Li B; Liu L; Gong Y; Bian J; Li X; Tang Y; Lei M; Chen D J Infect Dis; 2020 Mar; 221(Suppl 2):S156-S163. PubMed ID: 32176797 [TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness and mortality of colistin monotherapy versus colistin-fosfomycin combination therapy for the treatment of carbapenem-resistant Enterobacteriaceae (CRE) infections: A propensity score analysis. Katip W; Rayanakorn A; Oberdorfer P; Taruangsri P; Nampuan T; Okonogi S J Infect Public Health; 2024 May; 17(5):727-734. PubMed ID: 38513335 [TBL] [Abstract][Full Text] [Related]
8. Infections Caused by Carbapenem-Resistant Sheu CC; Chang YT; Lin SY; Chen YH; Hsueh PR Front Microbiol; 2019; 10():80. PubMed ID: 30761114 [TBL] [Abstract][Full Text] [Related]
9. A Cohort Study of the Impact of Carbapenem-Resistant Sabino S; Soares S; Ramos F; Moretti M; Zavascki AP; Rigatto MH mSphere; 2019 Apr; 4(2):. PubMed ID: 30971443 [TBL] [Abstract][Full Text] [Related]
10. Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children. Chiotos K; Hayes M; Gerber JS; Tamma PD J Pediatric Infect Dis Soc; 2020 Feb; 9(1):56-66. PubMed ID: 31872226 [TBL] [Abstract][Full Text] [Related]
11. Multicenter Study of the Risk Factors for Colonization or Infection with Carbapenem-Resistant Enterobacteriaceae in Children. Chiotos K; Tamma PD; Flett KB; Naumann M; Karandikar MV; Bilker WB; Zaoutis T; Han JH Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971864 [TBL] [Abstract][Full Text] [Related]
12. Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant Shortridge D; Kantro V; Castanheira M Microbiol Spectr; 2023 Feb; 11(1):e0450722. PubMed ID: 36622238 [TBL] [Abstract][Full Text] [Related]
14. Carbapenem-resistant Enterobacteriaceae: biology, epidemiology, and management. Temkin E; Adler A; Lerner A; Carmeli Y Ann N Y Acad Sci; 2014 Sep; 1323():22-42. PubMed ID: 25195939 [TBL] [Abstract][Full Text] [Related]
15. The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace. Logan LK; Weinstein RA J Infect Dis; 2017 Feb; 215(suppl_1):S28-S36. PubMed ID: 28375512 [TBL] [Abstract][Full Text] [Related]
17. Carbapenem-resistant Adesanya OA; Igwe HA AIMS Public Health; 2020; 7(4):804-815. PubMed ID: 33294483 [TBL] [Abstract][Full Text] [Related]
18. Global trends and hotspots in research of carbapenem-resistant Enterobacteriaceae (CRE): a bibliometric analysis from 2010 to 2020. Zhong H; Chen F; Li YJ; Zhao XY; Zhang ZL; Gu ZC; Yu YT Ann Palliat Med; 2021 Jun; 10(6):6079-6091. PubMed ID: 34237952 [TBL] [Abstract][Full Text] [Related]